NCT01757015View on ClinicalTrials.gov

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

NVA237

NVA237 (50µg, o.d. via SDDPI) in the morning,

DRUG

Placebo to NVA237

Placebo to NVA237

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY